CN112898232A - Selective targeting vimentin small molecule compound and preparation method and application thereof - Google Patents

Selective targeting vimentin small molecule compound and preparation method and application thereof Download PDF

Info

Publication number
CN112898232A
CN112898232A CN202110110479.4A CN202110110479A CN112898232A CN 112898232 A CN112898232 A CN 112898232A CN 202110110479 A CN202110110479 A CN 202110110479A CN 112898232 A CN112898232 A CN 112898232A
Authority
CN
China
Prior art keywords
compound
formula
small molecule
preparation
structural formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202110110479.4A
Other languages
Chinese (zh)
Other versions
CN112898232B (en
Inventor
欧田苗
汪晓娜
王世柯
欧阳光
陈玥如
苏晓萱
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sun Yat Sen University
Original Assignee
Sun Yat Sen University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Yat Sen University filed Critical Sun Yat Sen University
Priority to CN202210536404.7A priority Critical patent/CN114890965B/en
Priority to CN202110110479.4A priority patent/CN112898232B/en
Publication of CN112898232A publication Critical patent/CN112898232A/en
Application granted granted Critical
Publication of CN112898232B publication Critical patent/CN112898232B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/02—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions involving the formation of amino groups from compounds containing hydroxy groups or etherified or esterified hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
    • C07C217/14—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring
    • C07C217/18—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
    • C07C217/22—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted by carbon atoms having at least two bonds to oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The invention discloses a small molecular compound of selective targeting vimentin and a preparation method and application thereof, wherein the structural formula of the small molecular compound is shown as a formula (I) or a formula (II). Compared with the conventional vimentin binding molecule PQ7, the micromolecule compound prepared by the invention has more stable chemical property, stronger vimentin binding capacity and higher antitumor activity. But also has multiple advantages of proper molecular size, good water solubility, strong pharmacy and the like, and has extremely high application value and development prospect.

Description

Selective targeting vimentin small molecule compound and preparation method and application thereof
Technical Field
The invention belongs to the technical field of medicines and chemical engineering, and particularly relates to a small molecular compound of selective targeting vimentin, and a preparation method and application thereof.
Background
Cancer is one of the major diseases threatening human life health, wherein the invasion and metastasis of cancer are the main causes of the death of patients with solid tumors due to tumor spread and poor prognosis of patients. The existing anti-tumor migration drugs are still very deficient, and the development of the anti-tumor migration drugs has many problems and challenges, so that the development of good anti-tumor drugs is an important research direction in pharmacology.
Vimentin (vimentin) is the highest expressed component of the intermediate silk skeleton protein. Related researches show that the vimentin plays an important role in the metastatic deformation of tumors and tumor-related signal pathways, and the vimentin has abnormal expression and modification in various malignant tumors, including prostate cancer, melanoma, hepatocellular carcinoma, breast cancer, endometrial cancer and the like. However, the only chemotherapeutic drug targets currently known are cytoskeletal proteins (e.g., tubulin). Therefore, the development of a drug capable of targeting the proliferation and migration of vimentin against tumors is urgently needed.
Disclosure of Invention
The present invention is directed to solving at least one of the problems of the prior art described above. Therefore, the invention provides a small molecular compound which has stable chemical property, can target the vimentin and has the functions of resisting tumor proliferation and migration.
In a first aspect of the present invention, there is provided:
a small molecule compound, the structural formula of which is shown as formula (I) or formula (II):
Figure BDA0002919119750000011
Figure BDA0002919119750000021
wherein, in formula (I), X comprises carbon, oxygen, nitrogen, sulfur, an ester group, a carbonyl group or an amide;
r comprises any open chain compound, carbocycle, heterocycle, halogen, nitryl, cyano-group, amido, hydroxyl or sulfhydryl;
n is any integer of 1-4;
in formula (II), X comprises carbon, oxygen, nitrogen, sulfur, an ester group, a carbonyl group, or an amide;
r comprises any open chain compound, carbocycle, heterocycle, halogen, nitryl, cyano-group, amido, hydroxyl or sulfhydryl;
n is any integer of 1-4.
According to an embodiment of the present invention, at least the following advantages are provided: the micromolecular compound prepared by the invention has small molecular weight, is beneficial to quick absorption, and simultaneously has small steric hindrance, thereby being beneficial to the combination of the micromolecular compound and protein; secondly, the micromolecule compound prepared by the invention has certain linear structure and hydrophobicity, and the efficient combination of the micromolecule compound and the vimentin containing hydrophobic amino acid is promoted; furthermore, the small molecule compound prepared by the invention contains an ipsilateral double-chain structure, and can be helpful for the alpha-helix combination with the vimentin.
Furthermore, compared with the conventional vimentin binding molecule PQ7 (polyquaternium-7, CAS: 26590-05-6), it has anti-tumor activity, but because of its large molecular weight and large steric hindrance, it is not suitable for rapid absorption as a drug and is not favorable for binding with protein. Moreover, PQ7 has poor water solubility, thus reducing the drug potency. The micromolecule compound prepared by the invention overcomes the problems, has more stable chemical property and more obvious drug effect (combining vimentin and antitumor activity), and has multiple advantages of proper molecular size, good water solubility, strong drug forming property and the like.
According to a first aspect of the invention, when the structural formula of the small molecule compound is according to formula (II), the small molecule compound does not comprise:
(1) r is bromine;
(2) n is 2 and R is a structure represented by formula 29;
(3) n is 3 and R is a structure represented by formula 30;
wherein, the structure shown in formula 29 is:
Figure BDA0002919119750000031
the structure shown in formula 30 is:
Figure BDA0002919119750000032
according to the first aspect of the invention, the small molecule compound comprises a compound with a structure shown as a formula 6-28.
Of course, the compounds having the structures represented by the above formulas 6 to 28 are only preferable compounds in the present invention, and the compounds related to the present invention include, but are not limited to, the compounds having the structures represented by the above formulas 6 to 28.
In a second aspect of the present invention, there is provided:
a composition comprising a small molecule compound according to the first aspect of the invention.
In a third aspect of the present invention, there is provided:
the preparation method of the small molecule compound according to the first aspect comprises the following steps:
demethylating anisoyl in an acidic solution, adding a dibromoalkane chain, adjusting the pH to be alkaline, and adding a cyclic compound or a nitrogen-containing open-chain compound to obtain a micromolecular compound with a structural formula shown in a formula (II);
reacting the micromolecular compound with the structural formula shown as the formula (II) with 1, 2-phenylenediamine under an acidic condition to obtain the micromolecular compound with the structural formula shown as the formula (I);
the alpha helical structure is mainly in the secondary structure of the vimentin, and the hydrophobic amino acids in the structure can cause two vimentin monomers to be intertwined with each other to form a dimer. The preparation method provided by the third aspect of the present invention can synthesize a small molecule compound having a small molecular weight and having both linear and hydrophobic structures by using anisoyl as a raw material, and the small molecule compound can bind to the alpha helix of vimentin through the structures of two branches on the same side, thereby inhibiting dimerization of vimentin monomers.
According to the third aspect of the present invention, the cyclic compound includes an aromatic compound or a heterocyclic compound.
In some preferred embodiments of the present invention, the aromatic compound comprises: an aromatic compound containing dimethylamino group, an aromatic compound containing diethylamino group, an aromatic compound containing piperidyl group, an aromatic compound containing piperazinyl group, and benzene.
In some preferred embodiments of the present invention, the heterocyclic compound comprises: piperidinyl-containing heterocyclic compounds, piperazinyl-containing heterocyclic compounds, thiophenes, furans, tetrahydropyrrole, and morpholines.
The nitrogen-containing open chain compound comprises a dimethylamino open chain compound and a diethylamino open chain compound.
In some preferred embodiments of the invention, the dibromoalkane chain comprises 1, 2-dibromoethane, 1, 3-dibromoethane, and 1, 4-dibromoethane.
In some preferred embodiments of the invention, the demethylating agent is hydrobromic acid and the acidity regulator is acetic acid.
In a fourth aspect of the present invention, there is provided:
a medicament comprising a small molecule compound according to the first aspect of the invention or a pharmaceutically acceptable salt thereof.
Of course, the person skilled in the art can reasonably process the small molecule compound of the first aspect of the present invention further to obtain its stereoisomer or its prodrug molecule according to the actual situation.
According to the fourth aspect of the invention, the medicament further comprises pharmaceutically acceptable auxiliary materials.
According to a fourth aspect of the invention, the pharmaceutical dosage form comprises an injection, a tablet, a pill, a capsule, a suspension or an emulsion.
In a fifth aspect of the present invention, there is provided:
the use of a small molecule compound according to the first aspect of the invention in the preparation of a vimentin detection formulation.
In a sixth aspect of the present invention, there is provided:
the small molecule compound of the first aspect of the invention is used for preparing an anti-tumor medicament.
According to a sixth aspect of the invention, the tumour comprises one or more of ovarian cancer, cervical cancer, breast cancer, lung adenocarcinoma, colon cancer, liver cancer, leukaemia, non-small cell lung cancer, skin cancer, epithelial cell cancer, prostate cancer, nasopharyngeal carcinoma, glioblastoma, lymphoma or melanoma.
In some embodiments of the invention, the tumor is lung cancer, liver cancer, breast cancer, and colorectal cancer.
Drawings
The invention is further described with reference to the following figures and examples, in which:
FIG. 1 is a scheme showing the synthesis of compounds represented by general formulae (II) and (I);
FIG. 2 is a graph showing the response of the interaction between the compound prepared in the example of the present invention and vimentin (SPR);
FIG. 3 is a graphical representation of Western blot of compounds prepared in the examples of the present invention to promote autophagy of MDA-MB-231 tumor cells.
Detailed Description
The concept and technical effects of the present invention will be clearly and completely described below in conjunction with the embodiments to fully understand the objects, features and effects of the present invention. It is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all embodiments, and those skilled in the art can obtain other embodiments without inventive effort based on the embodiments of the present invention, and all embodiments are within the protection scope of the present invention.
The term "anisoyl" in reference to the following embodiments includes structurally identical compounds under different names as would be understood by one of skill in the art, including: 4,4 '-dimethoxyphenol ester and 4,4' -dimethoxybenzil.
Process for the preparation of compounds of the general formulae (II) and (I)
The synthetic scheme of the compounds in the examples of the invention is shown in figure 1.
As shown in fig. 1, anisoyl (compound 1) undergoes demethylation reaction in the environment of 40% hydrobromic acid acetic acid solution to obtain compound 2 (structural formula is shown in formula 2); reacting the compound 2 with dibromo alkane chains with different lengths to obtain an intermediate 3 (the structural formula is shown in the formula 3), an intermediate 4 (the structural formula is shown in the formula 4) and an intermediate 5 (the structural formula is shown in the formula 5); intermediate 3, intermediate 4 and intermediate 5 are respectively reacted with different nitrogen-containing aliphatic heterocyclic or nitrogen-containing non-heterocyclic substituent compounds under alkaline conditions (using K)2CO3Adjusting pH), reacting to obtain the compound shown as the general formula (II).
The compound shown in the general formula (II) is mixed with sodium acetate, and then acetic acid is used as a reaction solvent to react with 1, 2-phenylenediamine to obtain the compound shown in the general formula (I).
Wherein, the structural formula of the compound 2 in the above embodiment is:
Figure BDA0002919119750000051
the structural formula of the intermediate 3 is as follows:
Figure BDA0002919119750000061
the structural formula of the intermediate 4 is as follows:
Figure BDA0002919119750000062
the structural formula of the intermediate 5 is as follows:
Figure BDA0002919119750000063
the structural formula of the compound represented by the general formula (II) is:
Figure BDA0002919119750000064
the structural formula of the compound shown in the general formula (I) is as follows:
Figure BDA0002919119750000065
EXAMPLE 1 preparation of Compound 2
Mixing 4,4' -dimethoxybenzil (anisoyl, 18.50mmol) and 50mL of 40% hydrobromic acid acetic acid solution, stirring at 120 ℃ for reaction for 36 hours, monitoring the reaction completion by a TLC (thin layer chromatography) spot plate, and removing most of acid liquor in the solution by rotary evaporation, wherein an acid absorption device is adopted as the acid liquor removal mode. And (3) after rotary evaporation is carried out until a small amount of solution is remained, stirring in ice water until a yellow solid is separated out, carrying out suction filtration, and carrying out vacuum drying to obtain a yellow solid, namely the compound 2.
The compound 2 yield in this example was: 95.98 percent.
The hydrogen spectrum of compound 2 in this example is:
1H NMR(400MHz,DMSO)δ10.82(s,2H),7.76–7.72(m,4H),6.95–6.90(m,4H)。
EXAMPLE 2 preparation of intermediate 3
5.00g of the compound 2 prepared in example 1 (20.64mmol) were taken in with 23.27g of 1, 2-dibromoethane (123.85mmol) and 17.12g K2CO3(123.85mmol), adding appropriate amount of acetone or acetonitrile as solvent, stirring at 80 deg.C in oil bath for about 16h, monitoring by TLC spot plate, filtering to remove solid precipitate, and purifying by column chromatography with mobile phase of petroleum ether: 1-dichloromethane: 1 to give intermediate 3 as a pale yellow solid.
The yield of intermediate 3 in this example was: 40.53 percent.
The hydrogen spectrum of intermediate 3 in this example is:
1H NMR(400MHz,CDCl3)δ7.93(d,J＝8.9Hz,4H),6.95(d,J＝8.9Hz,4H),4.08(t,J＝5.9Hz,4H),3.48(t,J＝6.4Hz,4H),2.11–2.04(m,4H),2.02–1.94(m,4H)。
EXAMPLE 3 preparation of intermediate 4
5.00g of the compound 2(20.64mmol) prepared in example 1 above were taken in admixture with 25.00g of 1, 3-dibromopropane (123.85mmol) and 17.12g K2CO3(123.85mmol), adding appropriate amount of acetone or acetonitrile as solvent, stirring at 80 deg.C in oil bath for about 16h, monitoring by TLC spot plate, filtering to remove solid precipitate, and purifying by column chromatography with mobile phase of petroleum ether: 1-dichloromethane: 1 to give intermediate 4 as a pale yellow solid.
The yield of intermediate 4 in this example was: 41.53 percent.
The hydrogen spectrum of intermediate 4 in this example is:
1H NMR(400MHz,CDCl3)δ7.94(d,J＝8.9Hz,4H),6.97(d,J＝8.9Hz,4H),4.19(t,J＝5.8Hz,4H),3.60(t,J＝6.3Hz,4H),2.34(p,J＝6.1Hz,4H)。
EXAMPLE 4 preparation of intermediate 5
5.00g of the compound 2 prepared in example 1 (20.64mmol) were taken together with 26.74g of 1, 4-dibromobutane (123.85mmol) and 17.12g K2CO3(123.85mmol), adding appropriate amount of acetone or acetonitrile as solvent, stirring at 80 deg.C in oil bath for about 16h, monitoring by TLC spot plate, filtering to remove solid precipitate, and purifying by column chromatography with mobile phase of petroleum ether: 1-dichloromethane: 1 to give intermediate 5 as a pale yellow solid.
The yield of intermediate 5 in this example was: 20.22 percent.
The hydrogen spectrum of intermediate 5 in this example is:
1H NMR(400MHz,CDCl3)δ7.95(d,J＝9.0Hz,4H),6.98(d,J＝9.0Hz,4H),4.37(t,J＝6.2Hz,4H),3.66(t,J＝6.2Hz,4H)。
EXAMPLE 5 preparation of Compound C-1
According to the preparation of the compounds of the general formulae (II) and (I), 1g of intermediate 3(2.19mmol) from example 2 are taken and 448.03mg of piperidine (5.26mmol) and the appropriate amount of K are added2CO3Acetonitrile is used as a solvent, and the reaction is stirred at normal temperature. And (3) monitoring the complete reaction by TLC (thin layer chromatography) plates, filtering to remove solid precipitates, and performing column chromatography separation and purification, wherein the mobile phase conditions are methanol: dichloromethane ═ 2: 25 and a small amount of ammonia was added to give compound C-1 as a pale yellow solid.
The structural formula of compound C-1 in this example is shown in formula 6:
Figure BDA0002919119750000081
the yield of compound C-1 in this example was: 74.66 percent.
The hydrogen spectrum of compound C-1 in this example is:
1H NMR(400MHz,CDCl3)δ7.92(d,J＝8.9Hz,4H),6.96(d,J＝8.9Hz,4H),4.21(t,J＝5.9Hz,4H),2.83(t,J＝5.9Hz,4H),2.55(s,8H),1.67–1.59(m,8H),1.51–1.41(m,8H)。
the carbon spectrum of compound C-1 in this example is:
13C NMR(126MHz,CDCl3)δ193.58,164.19,132.42,126.35,114.91,66.44,57.64,55.11,25.90,24.15.11.10。
the electrospray mass spectrum (ESI-HRMS) of Compound C-1 in this example was:
[M+H]+m/z＝465.2748,calcd for 464.2675。
compound C-1 in this example was found to be 95.1% pure by HPLC.
EXAMPLE 6 preparation of Compound C-2
According to the preparation of the compounds of the general formulae (II) and (I), 1g of intermediate 3(2.19mmol) prepared in example 2 are taken and 237.22mg of dimethylamino (5.26mmol) and the appropriate amount of K are added2CO3Acetonitrile is used as a solvent, and the reaction is stirred at normal temperature. And (3) monitoring the complete reaction by TLC plates, filtering to remove solid precipitates, and performing column chromatography separation and purification, wherein the mobile phase is methanol: dichloromethane ═ 2: 25, Compound C-2 was obtained as a pale yellow solid.
The structural formula of compound C-2 in this example is shown in formula 7:
Figure BDA0002919119750000091
the yield of compound C-2 in this example was: 53.22 percent.
The hydrogen spectrum of compound C-2 in this example is:
1H NMR(400MHz,CDCl3)δ7.92(d,J＝8.9Hz,4H),6.97(d,J＝8.9Hz,4H),4.14(t,J＝5.6Hz,4H),2.76(t,J＝5.6Hz,4H),2.34(s,12H)。
the carbon spectrum of compound C-2 in this example is:
13C NMR(101MHz,CDCl3)δ193.49,164.09,132.36,126.34,114.82,66.34,57.96,45.85.11.10。
the electrospray mass spectrum (ESI-HRMS) of Compound C-2 in this example was:
[M+H]+m/z＝385.2122,calcd for 384.2049。
compound C-2 in this example was found to be 95.6% pure by HPLC.
EXAMPLE 7 preparation of Compound C-3
According to the preparation of the compounds of the general formulae (II) and (I), 1g of intermediate 3(2.19mmol) from example 2 are taken and added with tetrahydropyrrole (5.26mmol) and the appropriate amount of K2CO3Acetonitrile is used as a solvent, and the reaction is stirred at normal temperature. And (3) monitoring the complete reaction by TLC (thin layer chromatography) plates, filtering to remove solid precipitates, and performing column chromatography separation and purification, wherein the mobile phase conditions are methanol: 1-dichloromethane: 20, Compound C-3 was obtained as a pale yellow solid.
Figure BDA0002919119750000101
The hydrogen spectrum of compound C-3 in this example is:
1H NMR(400MHz,CDCl3)δ7.92(d,J＝8.8Hz,1H),6.98(d,J＝8.9Hz,1H),4.19(t,J＝5.8Hz,1H),2.94(t,J＝5.8Hz,1H),2.65(s,2H),1.82(s,2H)。
the carbon spectrum of compound C-3 in this example is:
13C NMR(101MHz,CDCl3)δ193.60,163.84,132.27,126.22,114.83,66.66,54.58,54.42,50.01,23.28.11.10。
the electrospray mass spectrum (ESI-HRMS) of Compound C-3 in this example was:
[M+H]+m/z＝437.2435,calcd for 436.2362。
compound C-3 in this example was 98.3% pure by HPLC.
EXAMPLE 8 preparation of Compound C-4
According to the general formulae (II) and (I)The preparation of the compound shown is carried out by taking 1g of intermediate 3(2.19mmol) prepared in example 2, adding 458.41mg of morpholine ring (5.26mmol) and the appropriate amount of K2CO3Acetonitrile is used as a solvent, and the reaction is stirred at normal temperature. And (3) monitoring the complete reaction by TLC (thin layer chromatography) plates, filtering to remove solid precipitates, and performing column chromatography separation and purification, wherein the mobile phase conditions are methanol: 1-dichloromethane: 20, Compound C-4 was obtained as a pale yellow solid.
The structural formula of compound C-4 in this example is shown in formula 9:
Figure BDA0002919119750000102
the yield of compound C-4 in this example was: 75.65 percent.
The hydrogen spectrum of compound C-4 in this example is:
1H NMR(400MHz,CDCl3)δ7.95(d,J＝8.9Hz,1H),6.98(d,J＝8.9Hz,1H),4.21(t,J＝5.6Hz,1H),3.79–3.67(m,2H),2.85(t,J＝5.6Hz,1H),2.65–2.54(m,2H)。
the carbon spectrum of compound C-4 in this example is:
13C NMR(101MHz,CDCl3)δ193.60,163.84,132.27,126.22,114.83,66.66,54.58,54.42,50.01,23.28.11.10。
the electrospray mass spectrum (ESI-HRMS) of Compound C-4 in this example was:
[M+H]+m/z＝469.2333,calcd for 486.2260。
compound C-4 in this example was 94.2% pure by HPLC.
EXAMPLE 9 preparation of Compound C-5
According to the preparation of the compounds of the general formulae (II) and (I), 1g of intermediate 3(2.19mmol) prepared in example 2 are taken and 453.23mg of pyridine (5.26mmol) and the appropriate amount of K are added2CO3Acetonitrile is used as a solvent, and the reaction is stirred at normal temperature. And (3) monitoring the complete reaction by TLC plates, filtering to remove solid precipitates, and performing column chromatography separation and purification, wherein the mobile phase is methanol: dichloromethane ═ 2: 25, obtainingCompound C-5 as a pale yellow solid.
The structural formula of compound C-5 in this example is shown in formula 10:
Figure BDA0002919119750000111
the yield of compound C-5 in this example was: 30.26 percent.
The hydrogen spectrum of compound C-5 in this example is:
1H NMR(400MHz,CDCl3)δ7.92(d,J＝8.9Hz,1H),6.96(d,J＝8.9Hz,1H),4.17(t,J＝5.8Hz,1H),2.99–2.87(m,2H),2.81(t,J＝5.8Hz,1H),2.55(s,2H),2.55(s,2H),2.05(s,1H)。
the carbon spectrum of compound C-5 in this example is:
13C NMR(101MHz,CDCl3)δ193.56,164.15,132.49,126.45,114.93,66.38,57.58,54.87,46.01.11.10。
the electrospray mass spectrum (ESI-HRMS) of Compound C-5 in this example was:
[M+H]+m/z＝467.2653,calcd for 466.2580。
compound C-5 in this example was 96.2% pure by HPLC.
EXAMPLE 10 preparation of Compound C-6
According to the preparation of the compounds of the general formulae (II) and (I), 1g of intermediate 4(2.07mmol) prepared in example 2 are taken and 233.48mg of piperidine (4.96mmol) and the appropriate amount of K are added2CO3Acetonitrile is used as a solvent, and the reaction is stirred at normal temperature. After TLC plate counting monitoring reaction is completely carried out, solid precipitate is removed by filtration, column chromatography separation and purification are carried out, and the flow phenomenon is methanol: 1-dichloromethane: 100, Compound C-5 was obtained as a pale yellow solid.
The structural formula of compound C-6 in this example is shown in formula 11:
Figure BDA0002919119750000121
the yield of compound C-6 in this example was: 43.83 percent.
The hydrogen spectrum of compound C-6 in this example is:
1H NMR(400MHz,CDCl3)δ7.92(d,J＝8.9Hz,4H),6.95(d,J＝9.0Hz,4H),4.11(t,J＝6.2Hz,4H),2.57(t,J＝25.5Hz,12H),2.13–2.04(m,4H),1.68(s,8H),1.53–1.44(m,4H)。
the carbon spectrum of compound C-6 in this example is:
13C NMR(126MHz,CDCl3)193.42,164.29,132.35,126.07,114.73,77.41,77.09,76.77,66.75,66.45,55.24,53.61,25.99.11.10。
the electrospray mass spectrum (ESI-HRMS) of Compound C-6 in this example was:
[M+H]+m/z＝493.3061,calcd for 492.2988。
compound C-6 in this example was found to be 95.1% pure by HPLC.
EXAMPLE 11 preparation of Compound C-7
According to the preparation of the compounds of the general formulae (II) and (I), 1g of intermediate 4(2.07mmol) prepared in example 2 was taken and 233.48mg of dimethylamine (4.96mmol) and the appropriate amount of K were added2CO3Acetonitrile is used as a solvent, and the reaction is stirred at normal temperature. After TLC plate counting monitoring reaction is completely carried out, solid precipitate is removed by filtration, column chromatography separation and purification are carried out, and the flow phenomenon is methanol: 1-dichloromethane: 100, Compound C-7 was obtained as a pale yellow solid.
The structural formula of compound C-7 in this example is shown in formula 12:
Figure BDA0002919119750000131
the yield of compound C-7 in this example was: 43.83 percent.
The hydrogen spectrum of compound C-7 in this example is:
1H NMR(400MHz,CDCl3)δ7.91(d,J＝8.9Hz,4H),6.95(d,J＝8.9Hz,4H),4.08(t,J＝6.4Hz,4H),2.45(t,J＝7.2Hz,4H),2.25(s,12H),1.97(dt,J＝13.4,6.6Hz,4H)。
the carbon spectrum of compound C-7 in this example is:
13C NMR(126MHz,CDCl3)δ193.67,164.43,132.48,126.32,114.86,66.65,56.18,45.43,27.19.11.10。
the electrospray mass spectrum (ESI-HRMS) of Compound C-7 in this example was:
[M+H]+m/z＝413.2435,calcd for 412.2362。
compound C-7 in this example was 94.7% pure by HPLC.
EXAMPLE 12 preparation of Compound C-8
According to the preparation of the compounds of the general formulae (II) and (I), 1g of intermediate 4(2.07mmol) from example 2 are taken and 352.54mg of tetrahydropyrrole (4.96mmol) and the appropriate amount of K are added2CO3Acetonitrile is used as a solvent, and the reaction is stirred at normal temperature. And (3) after TLC plate counting monitoring reaction is completely carried out, filtering to remove solid precipitate, and carrying out column chromatography separation and purification, wherein the separation conditions are methanol: dichloromethane ═ 2: 25, Compound C-8 was obtained as a pale yellow solid.
The structural formula of compound C-8 in this example is shown in formula 13:
Figure BDA0002919119750000132
the yield of compound C-8 in this example was: 73.54 percent.
The hydrogen spectrum of compound C-8 in this example is:
1H NMR(400MHz,CDCl3)δ7.91(d,J＝8.9Hz,4H),6.95(d,J＝8.9Hz,4H),4.11(t,J＝6.4Hz,4H),2.68–2.60(m,4H),2.56(t,J＝5.8Hz,8H),2.09–1.99(m,4H),1.82–1.75(m,8H)。
the carbon spectrum of compound C-8 in this example is:
13C NMR(126MHz,CDCl3)δ193.65,164.34,132.49,126.35,114.86,66.66,54.27,53.01,28.16,23.56.11.10。
the electrospray mass spectrum (ESI-HRMS) of Compound C-8 in this example was:
[M+H]+m/z＝465.2748,calcd for464.2675。
compound C-8 in this example was 93.6% pure by HPLC.
EXAMPLE 13 preparation of Compound C-9
According to the preparation of the compounds of the general formulae (II) and (I), 1g of intermediate 4(2.07mmol) from example 2 are taken and 431.85mg of morpholine (4.96mmol) and the appropriate amount of K are added2CO3Acetonitrile is used as a solvent, and the reaction is stirred at normal temperature. And (3) after TLC plate counting monitoring reaction is completely carried out, filtering to remove solid precipitate, and carrying out column chromatography separation and purification, wherein the separation conditions are methanol: 1-dichloromethane: 20, Compound C-9 was obtained as a pale yellow solid.
The structural formula of compound C-9 in this example is shown in formula 14:
Figure BDA0002919119750000141
the yield of compound C-9 in this example was: 75.22 percent.
The hydrogen spectrum of compound C-9 in this example is:
1H NMR(400MHz,CDCl3)δ7.92(d,J＝8.8Hz,4H),6.95(d,J＝8.8Hz,4H),4.10(t,J＝6.3Hz,4H),3.75–3.67(m,8H),2.52(t,J＝7.2Hz,4H),2.46(s,8H),2.04–1.94(m,4H)。
the carbon spectrum of compound C-9 in this example is:
13C NMR(126MHz,CDCl3)δ193.60,164.40,132.50,126.36,114.85,66.88,66.57,55.39,53.75,26.14.11.10。
the electrospray mass spectrum (ESI-HRMS) of Compound C-9 in this example was:
[M+H]+m/z＝465.2748,calcd for 496.2573。
compound C-9 in this example was 96.4% pure by HPLC.
EXAMPLE 14 preparation of Compound C-10
According to the general formulae (II) and (I)The preparation of the compound shown is carried out by taking 1g of intermediate 4(2.07mmol) prepared in example 2, adding 426.97mg of pyridine (4.96mmol) and the appropriate amount of K2CO3Acetonitrile is used as a solvent, and the reaction is stirred at normal temperature. And (3) monitoring the complete reaction by TLC (thin layer chromatography) plates, filtering to remove solid precipitates, and performing column chromatography separation and purification, wherein the conditions of a mobile phase are as follows: 25 and a small amount of ammonia was added to give compound C-10 as a pale yellow solid.
The structural formula of compound C-10 in this example is shown in formula 15:
Figure BDA0002919119750000151
the yield of compound C-10 in this example was: 21.52 percent.
The hydrogen spectrum of compound C-10 in this example is:
1H NMR(500MHz,CDCl3)δ7.92(d,J＝8.4Hz,1H),6.96(d,J＝8.9Hz,1H),4.09(t,J＝4.8Hz,1H),2.91(s,2H),2.63–2.47(m,2H),2.05–1.93(m,1H)。
the carbon spectrum of compound C-10 in this example is:
13C NMR(101MHz,CDCl3)δ193.60,163.84,132.27,126.22,114.83,66.66,54.58,54.42,50.01,23.28.11.10。
the electrospray mass spectrum (ESI-HRMS) of Compound C-10 in this example was:
[M+H]+m/z＝495.2966,calcd for 494.2893。
compound C-10 in this example was 94.1% pure by HPLC.
EXAMPLE 15 preparation of Compound C-11
According to the preparation of the compounds of the general formulae (II) and (I), 1g of intermediate 5(1.95mmol) from example 2 are taken and 398.96mg of piperidine (4.69mmol) and the appropriate amount of K are added2CO3Acetonitrile is used as a solvent, and the reaction is stirred at normal temperature. And (3) monitoring the complete reaction by TLC plates, filtering to remove solid precipitates, and performing column chromatography separation and purification, wherein the mobile phase is methanol: dichloromethane ═ 2: 25, obtaining a lightCompound C-11 as a yellow solid.
The structural formula of compound C-11 in this example is shown in formula 16:
Figure BDA0002919119750000161
the yield of compound C-11 in this example was: 72.44 percent.
The hydrogen spectrum of compound C-11 in this example is:
1H NMR(400MHz,DMSO)δ7.84(d,J＝8.9Hz,4H),7.12(d,J＝8.9Hz,4H),4.11(t,J＝6.5Hz,4H),2.37–2.23(m,12H),1.79–1.69(m,4H),1.60–1.51(m,4H),1.50–1.43(m,4H),1.41–1.33(m,4H)。
the carbon spectrum of compound C-11 in this example is:
13C NMR(126MHz,CDCl3)δ193.68,164.47,132.46,126.23,114.82,68.27,58.82,54.53,27.21,25.75,24.35,23.19.11.10。
the electrospray mass spectrum (ESI-HRMS) of Compound C-11 in this example was:
[M+H]+m/z＝521.3374,calcd for520.3301。
compound C-11 in this example was 93.8% pure by HPLC.
EXAMPLE 16 preparation of Compound C-12
According to the preparation of the compounds of the general formulae (II) and (I), 1g of intermediate 5(1.95mmol) from example 2 are taken and 333.23mg of tetrahydropyrrole (4.69mmol) and the appropriate amount of K are added2CO3Acetonitrile is used as a solvent, and the reaction is stirred at normal temperature. And (3) monitoring the complete reaction by TLC (thin layer chromatography) plates, filtering to remove solid precipitates, and performing column chromatography separation and purification, wherein the mobile phase conditions are methanol: dichloromethane ═ 2: 25, Compound C-12 was obtained as a pale yellow solid.
The structural formula of compound C-12 in this example is shown in formula 17:
Figure BDA0002919119750000162
the yield of compound C-12 in this example was: 48.13 percent.
The hydrogen spectrum of compound C-12 in this example is:
1H NMR(400MHz,CDCl3)δ7.89(d,J＝8.7Hz,4H),6.92(d,J＝8.7Hz,4H),4.04(t,J＝6.3Hz,4H),2.61–2.47(m,12H),1.86–1.65(m,16H)。
the carbon spectrum of compound C-12 in this example is:
13C NMR(126MHz,CDCl3)δ193.57,164.36,132.34,126.11,114.71,68.14,55.95,54.12,27.08,25.24,23.39.11.10。
the electrospray mass spectrum (ESI-HRMS) of Compound C-12 in this example was:
[M+H]+m/z＝493.3061,calcd for 492.2988。
compound C-12 in this example was 96.8% pure by HPLC.
EXAMPLE 17 preparation of Compound C-13
According to the preparation of the compounds of the general formulae (II) and (I), 1g of intermediate 5(1.95mmol) from example 2 are taken and 408.19mg of morpholine (4.69mmol) and the appropriate amount of K are added2CO3Acetonitrile is used as a solvent, and the reaction is stirred at normal temperature. And (3) monitoring the complete reaction by TLC (thin layer chromatography) plates, filtering to remove solid precipitates, and performing column chromatography separation and purification, wherein the mobile phase conditions are methanol: 1-dichloromethane: 20, Compound C-13 was obtained as a pale yellow solid.
The structural formula of compound C-13 in this example is shown in formula 18:
Figure BDA0002919119750000171
the yield of compound C-13 in this example was: 66.52 percent.
The hydrogen spectrum of compound C-13 in this example is:
1H NMR(400MHz,CDCl3)δ7.92(d,J＝8.9Hz,4H),6.94(d,J＝8.9Hz,4H),4.06(t,J＝6.3Hz,4H),3.76–3.66(m,8H),2.52–2.36(m,12H),1.89–1.79(m,4H),1.74–1.63(m,4H)。
the carbon spectrum of compound C-13 in this example is:
13C NMR(101MHz,CDCl3)δ193.61,164.38,132.45,126.14,114.79,68.11,66.65,58.42,53.55,26.94,22.72.11.10。
the electrospray mass spectrum (ESI-HRMS) of Compound C-13 in this example was:
[M+H]+m/z＝525.2934,calcd for 524.2886。
compound C-13 in this example was 96.8% pure by HPLC.
EXAMPLE 18 preparation of Compound B-1
According to the preparation method of the compounds represented by the general formulae (II) and (I), 200mg of the compound C-1(452.38mmol) prepared in the above example 5 was taken, 49.54mg of 1, 2-phenylenediamine (458.14mmol) and an appropriate amount of sodium acetate were added, and the mixture was stirred and reacted at 120 ℃ for 24 hours with acetic acid as a solvent. And (3) monitoring the complete reaction by TLC (thin layer chromatography) plate, diluting with ice water, adjusting the pH of the solution to be neutral by using sodium bicarbonate, extracting with dichloromethane, washing the extract for 2-3 times, and performing column chromatography separation and purification, wherein the mobile phase conditions are that 1: 25, Compound B-1 was obtained as a yellow solid having blue fluorescence.
The structural formula of compound B-1 in this example is shown in formula 19:
Figure BDA0002919119750000181
the yield of compound B-1 in this example was: 52.25 percent.
The hydrogen spectrum of compound B-1 in this example is:
1H NMR(400MHz,CDCl3)δ8.10(dd,J＝6.3,3.4Hz,2H),7.69(dd,J＝6.4,3.4Hz,2H),7.46(d,J＝8.7Hz,4H),6.86(d,J＝8.7Hz,4H),4.12(t,J＝6.0Hz,4H),2.77(t,J＝6.0Hz,4H),2.50(s,8H),1.60(dt,J＝11.0,5.6Hz,8H),1.48–1.38(m,4H)。
the carbon spectrum of compound B-1 in this example is:
13C NMR(101MHz,CDCl3)δ159.16,152.99,141.08,131.91,131.27,129.59,129.02,114.46,57.65,54.97,25.42,23.82.11.10。
the electrospray mass spectrum (ESI-HRMS) of Compound B-1 in this example was:
[M+H]+m/z＝537.3224,calcd for 536.3151。
compound B-1 in this example was 94.7% pure by HPLC.
EXAMPLE 19 preparation of Compound B-2
According to the preparation method of the compounds shown in the general formulas (II) and (I), 200mg of the compound C3 (458.46mmol) prepared in the example 7 is taken, 59.49mg of 1, 2-phenylenediamine (550.16mmol) and a proper amount of sodium acetate are added, and the mixture is stirred and reacted for 24 hours at 120 ℃ by taking acetic acid as a solvent. And (3) monitoring the complete reaction by TLC (thin layer chromatography) plate, diluting with ice water, adjusting the pH of the solution to be neutral by using sodium bicarbonate, extracting with dichloromethane, washing the extract for 2-3 times, and performing column chromatography separation and purification, wherein the mobile phase conditions are that 1: 25, obtaining the crude product, and purifying by thin-layer chromatography (large plate) with the developing solvent of methanol: ammonia water: dichloromethane 10: 1: 300, Compound B-2 was obtained as a yellow solid having blue fluorescence.
The structural formula of compound B-2 in this example is shown in formula 20:
Figure BDA0002919119750000191
the yield of compound B-2 in this example was: 48.75 percent.
The hydrogen spectrum of compound B-2 in this example is:
1H NMR(400MHz,CDCl3)δ8.14(dd,J＝6.4,3.4Hz,1H),7.73(dd,J＝6.4,3.4Hz,1H),7.49(d,J＝8.8Hz,2H),6.90(d,J＝8.8Hz,2H),4.17(t,J＝5.9Hz,2H),2.95(t,J＝5.9Hz,2H),2.68(t,J＝6.0Hz,4H),1.84(t,J＝5.1Hz,4H)。
the carbon spectrum of compound B-2 in this example is:
13C NMR(126MHz,CDCl3)δ159.46,153.15,141.17,131.89,131.34,129.64,129.11,114.55,67.02,55.07,54.87,23.59.11.10。
the electrospray mass spectrum (ESI-HRMS) of Compound B-2 in this example was:
[M+H]+m/z＝509.2911,calcd for 508.2838。
compound B-2 in this example was 93.3% pure by HPLC.
EXAMPLE 20 preparation of Compound B-3
According to the preparation method of the compounds shown in the general formulas (II) and (I), 200mg of the compound C6(405.96mmol) prepared in the example 10 is taken, 52.68mg of 1, 2-phenylenediamine (487.15mmol) and a proper amount of sodium acetate are added, and the mixture is stirred and reacted for 24 hours at 120 ℃ by taking acetic acid as a solvent. And (3) monitoring the complete reaction by TLC (thin layer chromatography) plate, diluting with ice water, adjusting the pH of the solution to be neutral by using sodium bicarbonate, extracting with dichloromethane, washing the extract for 2-3 times, and performing column chromatography separation and purification, wherein the mobile phase conditions are that 1: 25, Compound B-3 was obtained as a yellow solid having blue fluorescence.
The structural formula of compound B-3 in this example is shown in formula 21:
Figure BDA0002919119750000201
the yield of compound B-3 in this example was: 45.24 percent.
The hydrogen spectrum of compound B-3 in this example is:
1H NMR(400MHz,CDCl3)δ8.12(dd,J＝6.3,3.4Hz,2H),7.72(dd,J＝6.4,3.4Hz,2H),7.47(d,J＝8.7Hz,4H),6.88(t,J＝9.1Hz,4H),4.15(t,J＝5.9Hz,4H),2.81(t,J＝5.9Hz,4H),2.58(d,J＝17.9Hz,8H),1.68–1.60(m,8H),1.49–1.43(m,4H),1.25(s,4H)。
the carbon spectrum of compound B-3 in this example is:
13C NMR(126MHz,CDCl3)δ159.39,153.14,141.21,131.98,131.38,129.69,129.15,122.34,114.59,65.84,57.83,55.13,29.84,25.72,24.07.11.10。
the electrospray mass spectrum (ESI-HRMS) of Compound B-3 in this example was:
[M+H]+m/z＝509.2911,calcd for 508.2838。
compound B-3 in this example was found to be 95.5% pure by HPLC.
EXAMPLE 21 preparation of Compound B-4
According to the preparation method of the compounds represented by the general formulas (II) and (I), 200mg of the compound C7(484.81mmol) prepared in the above example 11 was taken, 62.91mg of 1, 2-phenylenediamine (581.78mmol) and an appropriate amount of sodium acetate were added, and the mixture was stirred and reacted at 120 ℃ for 24 hours with acetic acid as a solvent. And (3) monitoring the complete reaction by TLC (thin layer chromatography) plate, diluting with ice water, adjusting the pH of the solution to be neutral by using sodium bicarbonate, extracting with dichloromethane, washing the extract for 2-3 times, and performing column chromatography separation and purification, wherein the mobile phase conditions are that 1: 25, Compound B-4 was obtained as a yellow solid having blue fluorescence.
The structural formula of compound B-4 in this example is shown in formula 22:
Figure BDA0002919119750000202
Figure BDA0002919119750000211
the yield of compound B-4 in this example was: 45.68 percent.
The hydrogen spectrum of compound B-4 in this example is:
1H NMR(400MHz,CDCl3)δ8.11(dd,J＝6.4,3.4Hz,2H),7.71(dd,J＝6.4,3.4Hz,2H),7.47(d,J＝8.8Hz,4H),6.86(d,J＝8.8Hz,4H),4.04(t,J＝6.4Hz,4H),2.52–2.45(m,4H),2.28(s,12H),1.98(dt,J＝13.5,6.5Hz,4H)。
the carbon spectrum of compound B-4 in this example is:
13C NMR(101MHz,CDCl3)δ159.62,153.11,141.07,131.63,131.27,129.56,129.02,114.36,66.23,56.38,45.49,27.42.11.10。
the electrospray mass spectrum (ESI-HRMS) of Compound B-4 in this example was:
[M+H]+m/z＝485.2911,calcd for 484.2838。
compound B-4 in this example was 96.1% pure by HPLC.
EXAMPLE 22 preparation of Compound B-5
According to the preparation method of the compounds represented by the general formulas (II) and (I), 200mg of the compound C8(430.47mmol) prepared in the above example 12 is taken, 55.86mg of 1, 2-phenylenediamine (516.56mmol) and a proper amount of sodium acetate are added, and the mixture is stirred and reacted for 24 hours at 120 ℃ by taking acetic acid as a solvent. And (3) monitoring the complete reaction by TLC (thin layer chromatography) plate, diluting with ice water, adjusting the pH of the solution to be neutral by using sodium bicarbonate, extracting with dichloromethane, washing the extract for 2-3 times, and performing column chromatography separation and purification, wherein the mobile phase conditions are that 1: 25, Compound B-5 was obtained as a yellow solid having blue fluorescence.
The structural formula of compound B-5 in this example is shown in formula 23:
Figure BDA0002919119750000212
the yield of compound B-5 in this example was: 38.25 percent.
The hydrogen spectrum of compound B-5 in this example is:
1H NMR(400MHz,CDCl3)δ8.11(dd,J＝6.3,3.4Hz,2H),7.71(dd,J＝6.4,3.4Hz,2H),7.47(d,J＝8.7Hz,4H),6.86(d,J＝8.7Hz,4H),4.05(t,J＝6.4Hz,4H),2.74–2.61(m,4H),2.56(s,8H),2.09–1.96(m,4H),1.80(s,8H)。
the carbon spectrum of compound B-5 in this example is:
13C NMR(101MHz,CDCl3)δ159.55,152.99,140.97,131.51,131.18,129.44,128.92,114.27,66.33,54.19,53.08,28.66,23.41.11.10。
the electrospray mass spectrum (ESI-HRMS) of Compound B-5 in this example was:
[M+H]+m/z＝537.3209,calcd for 536.3151。
compound B-5 in this example was found to be 95.8% pure by HPLC.
EXAMPLE 23 preparation of Compound B-6
According to the preparation method of the compounds represented by the general formulas (II) and (I), 200mg of the compound C9(402.74mmol) prepared in the above example 13 is taken, 52.26mg of 1, 2-phenylenediamine (483.29mmol) and a proper amount of sodium acetate are added, and the mixture is stirred and reacted for 24 hours at 120 ℃ by taking acetic acid as a solvent. And (3) monitoring the complete reaction by TLC (thin layer chromatography) plate, diluting with ice water, adjusting the pH of the solution to be neutral by using sodium bicarbonate, extracting with dichloromethane, washing the extract for 2-3 times, and performing column chromatography separation and purification, wherein the mobile phase conditions are that 1: 25, Compound B-6 was obtained as a yellow solid having blue fluorescence.
The structural formula of compound B-6 in this example is shown in formula 24:
Figure BDA0002919119750000221
the yield of compound B-6 in this example was: 52.81 percent.
The hydrogen spectrum of compound B-6 in this example is:
1H NMR(400MHz,CDCl3)δ8.12(dd,J＝6.4,3.4Hz,2H),7.72(dd,J＝6.4,3.4Hz,2H),7.48(d,J＝8.7Hz,4H),6.86(d,J＝8.8Hz,4H),4.06(t,J＝6.3Hz,4H),3.79–3.72(m,8H),2.61–2.55(m,4H),2.52(s,8H),2.02(dt,J＝13.5,6.6Hz,8H)。
the carbon spectrum of compound B-6 in this example is:
13C NMR(126MHz,CDCl3)δ159.56,153.01,141.07,131.72,131.25,129.56,129.00,66.91,66.14,55.54,53.73,26.34.11.10。
the electrospray mass spectrum (ESI-HRMS) of Compound B-6 in this example was:
[M+H]+m/z＝569.3122,calcd for 568.3050。
compound B-6 in this example was 94.0% pure by HPLC.
EXAMPLE 24 preparation of Compound B-7
According to the preparation method of the compounds represented by the general formulas (II) and (I), 200mg of the compound C11(384.09mmol) prepared in the above example 15 is taken, 49.84mg of 1, 2-phenylenediamine (460.91mmol) and a proper amount of sodium acetate are added, and the mixture is stirred and reacted for 24 hours at 120 ℃ by taking acetic acid as a solvent. And (3) monitoring the complete reaction by TLC (thin layer chromatography) plate, diluting with ice water, adjusting the pH of the solution to be neutral by using sodium bicarbonate, extracting with dichloromethane, washing the extract for 2-3 times, and performing column chromatography separation and purification, wherein the mobile phase conditions are that 1: 25, Compound B-7 was obtained as a yellow solid having blue fluorescence.
The structural formula of compound B-7 in this example is shown in formula 25:
Figure BDA0002919119750000231
the yield of compound B-7 in this example was: 33.26 percent.
The hydrogen spectrum of compound B-7 in this example is:
1H NMR(400MHz,CDCl3)δ8.12(dd,J＝6.4,3.4Hz,2H),7.72(dd,J＝6.4,3.4Hz,2H),7.47(d,J＝8.7Hz,4H),6.85(d,J＝8.7Hz,4H),4.00(t,J＝6.2Hz,4H),2.55–2.38(m,12H),1.86–1.77(m,4H),1.75–1.69(m,4H),1.67–1.59(m,4H),1.49–1.42(m,4H)。
the carbon spectrum of compound B-7 in this example is:
13C NMR(126MHz,CDCl3)δ159.68,153.08,141.05,131.54,131.23,129.46,128.99,114.32,67.82,59.07,54.60,27.40,25.97,24.48,23.47.11.10。
the electrospray mass spectrum (ESI-HRMS) of Compound B-7 in this example was:
[M+H]+m/z＝593.3848,calcd for 592.3777。
compound B-7 in this example was 98.1% pure by HPLC.
EXAMPLE 25 preparation of Compound B-8
According to the preparation method of the compounds represented by the general formulas (II) and (I), 200mg of the compound C12(453.95mmol) prepared in the above example 16 was taken, 58.91mg of 1, 2-phenylenediamine (544.74mmol) and an appropriate amount of sodium acetate were added, and the mixture was stirred and reacted at 120 ℃ for 24 hours with acetic acid as a solvent. And (3) monitoring the complete reaction by TLC (thin layer chromatography) plate, diluting with ice water, adjusting the pH of the solution to be neutral by using sodium bicarbonate, extracting with dichloromethane, washing the extract for 2-3 times, and performing column chromatography separation and purification, wherein the mobile phase conditions are that 1: 25, Compound B-8 was obtained as a yellow solid having blue fluorescence.
The structural formula of compound B-8 in this example is shown in formula 26:
Figure BDA0002919119750000241
the yield of compound B-8 in this example was: 28.55 percent.
The hydrogen spectrum of compound B-8 in this example is:
1H NMR(400MHz,CDCl3)δ7.92(d,J＝8.9Hz,4H),6.94(d,J＝8.9Hz,4H),4.06(t,J＝6.3Hz,4H),3.76–3.66(m,8H),2.52–2.36(m,12H),1.89–1.79(m,4H),1.74–1.63(m,4H)。
the carbon spectrum of compound B-8 in this example is:
13C NMR(126MHz,CDCl3)δ159.77,153.21,141.19,131.73,131.35,129.61,129.12,114.46,67.86,59.46,45.47,27.21,24.24.11.10。
the electrospray mass spectrum (ESI-HRMS) of Compound B-8 in this example was:
[M+H]+m/z＝513.3224,calcd for 512.3151。
compound B-8 in this example was 96.2% pure by HPLC.
EXAMPLE 26 preparation of Compound B-9
According to the preparation method of the compounds represented by the general formulas (II) and (I), 200mg of the compound C13(405.95mmol) prepared in the above example 17 was taken, 52.68mg of 1, 2-phenylenediamine (487.14mmol) and an appropriate amount of sodium acetate were added, and the mixture was stirred and reacted at 120 ℃ for 24 hours with acetic acid as a solvent. And (3) monitoring the complete reaction by TLC (thin layer chromatography) plate, diluting with ice water, adjusting the pH of the solution to be neutral by using sodium bicarbonate, extracting with dichloromethane, washing the extract for 2-3 times, and performing column chromatography separation and purification, wherein the mobile phase conditions are that 1: 25, Compound B-9 was obtained as a yellow solid having blue fluorescence.
The structural formula of compound B-9 in this example is shown in formula 27:
Figure BDA0002919119750000251
the yield of compound B-9 in this example was: 40.68 percent.
The hydrogen spectrum of compound B-9 in this example is:
1H NMR(400MHz,CDCl3)δ8.12(dd,J＝6.4,3.4Hz,2H),7.72(dd,J＝6.4,3.4Hz,2H),7.50–7.45(m,4H),6.85(d,J＝8.8Hz,4H),4.00(t,J＝6.3Hz,4H),3.76–3.70(m,8H),2.50–2.40(m,12H),1.87–1.78(m,4H),1.75–1.65(m,4H)。
the carbon spectrum of compound B-9 in this example is:
13C NMR(126MHz,CDCl3)δ159.69,153.10,141.13,131.70,131.32,129.59,129.07,114.37,67.78,67.05,58.70,53.80,27.24,23.14.11.10。
the electrospray mass spectrum (ESI-HRMS) of Compound B-9 in this example was:
[M+H]+m/z＝597.3435,calcd for 564.3463。
compound B-9 in this example was 96.5% pure by HPLC.
EXAMPLE 27 preparation of Compound B-10
According to the preparation method of the compounds represented by the general formulas (II) and (I), 200mg of the compound C14(381.20mmol) prepared in the above example 18 was taken, 49.47mg of 1, 2-phenylenediamine (457.44mmol) and an appropriate amount of sodium acetate were added, and the mixture was stirred and reacted at 120 ℃ for 24 hours with acetic acid as a solvent. And (3) monitoring the complete reaction by TLC (thin layer chromatography) plate, diluting with ice water, adjusting the pH of the solution to be neutral by using sodium bicarbonate, extracting with dichloromethane, washing the extract for 2-3 times, and performing column chromatography separation and purification, wherein the mobile phase conditions are that 1: 25, Compound B-10 was obtained as a yellow solid having blue fluorescence.
The structural formula of compound B-10 in this example is shown in formula 28:
Figure BDA0002919119750000252
Figure BDA0002919119750000261
the yield of compound B-10 in this example was: 15.28 percent.
The hydrogen spectrum of compound B-10 in this example is:
1H NMR(400MHz,CDCl3)δ8.12(dd,J＝6.4,3.5Hz,2H),7.72(dd,J＝6.3,3.4Hz,2H),7.47(d,J＝8.6Hz,4H),6.85(d,J＝8.7Hz,4H),4.00(t,J＝6.1Hz,4H),3.13–3.06(m,4H),2.69–2.63(m,4H),2.52–2.46(m,4H),2.31(s,10H),1.87–1.77(m,4H),1.75–1.63(m,4H)。
the carbon spectrum of compound B-10 in this example is:
13C NMR(101MHz,CDCl3)δ159.73,153.19,141.16,131.69,131.35,129.65,129.09,114.42,67.85,58.87,54.21,45.91,27.33,23.29.11.10。
the electrospray mass spectrum (ESI-HRMS) of Compound B-10 in this example was:
[M+H]+m/z＝595.3755,calcd for 596.3363。
compound B-10 in this example was found to be 95.1% pure by HPLC.
Assay of the binding Effect of vimentin of the Compound prepared in the above example
The surface plasmon resonance technology is used for testing the binding effect of the compound prepared in the embodiment 1-28 and the vimentin, and the specific steps are as follows:
1. the vimentin is diluted by sodium acetate solution (pH5.5) to make the final concentration be 100mM, and is marked on an NTA chip;
2. diluting the test compound to 50mM with SPR buffer, setting a program, allowing the test compound to flow through the NTA chip, and washing the NTA chip with SPR buffer after the test compound is combined with the vimentin to dissociate the test compound;
3. and fitting the equilibrium dissociation constant KD value of the compound to be tested and the vimentin.
In this case, PQ7 (polyquaternium-7, CAS: 26590-05-6) was used as a control. PQ7 is a small molecule that specifically binds vimentin.
The equilibrium dissociation constant KD values of the test compound and vimentin are shown in table 1.
TABLE 1 equilibrium dissociation constant KD values for test compounds and vimentin
Figure BDA0002919119750000262
Figure BDA0002919119750000271
Meanwhile, the response value of the compound to be detected and the vimentin is obtained through calculation, and the binding capacity and the binding mode of the compound to be detected and the vimentin are preliminarily judged according to the response value and the dissociation curve, and the result is shown in fig. 2.
From the results, it is understood that the compounds prepared in the above examples have strong binding ability to vimentin, and most of them are superior to PQ 7.
Detection of inhibitory Effect of the Compounds prepared in the above examples on the growth of tumor cells
Selecting the compound with stronger binding effect on vimentin in the above embodiment, and carrying out in vitro cytotoxicity detection on various tumor cell strains by using an MTT method.
The tumor cell strain used is: a549 human non-small cell lung cancer cell, HEK293T human embryonic kidney epithelial cell, HepG2 human liver cancer cell, MDA-MB-231 human breast cancer cell, HUVEC human umbilical vein vascular endothelial cell, SW480 human colon cancer cell, DLD-1 human colorectal adenocarcinoma epithelial cell.
The method comprises the following specific steps: adding the compounds to be detected with different concentrations into the cells in the logarithmic growth phase respectively, incubating for 24h, adding MTT, and determining the absorbance. The concentration of the compound at which the growth of the cells was inhibited by 50% (IC50 value) was calculated, and the results are shown in Table 2.
TABLE 2 inhibition of growth (IC) of various tumor cell lines by test compounds50Value/. mu.M)
Figure BDA0002919119750000272
Figure BDA0002919119750000281
From the results, it is understood that the IC50 of the compounds prepared in the above examples is lower than that of PQ7, indicating that the compounds prepared in the above examples have a stronger inhibitory activity against various tumor cells.
Test of the Effect of the Compounds prepared in the above examples on tumor autophagy
Western blot is adopted to detect the effect of the compound prepared in the embodiment on tumor autophagy, and the specific steps are as follows:
cells were cultured (MDA-MB-231 tumor cells were used as the subject), and total supernatant protein was extracted by adding cell lysate. The total protein concentration was measured using the BCA method, and then the protein was denatured. And (3) taking the same mass of protein for loading, and separating protein bands by SDS-PAGE electrophoresis. And (3) calculating the molecular weight according to the target protein, cutting off the electrophoresis gel band at the corresponding position, and transferring the protein band to the PVDF membrane by a wet transfer method.
A5% skim milk powder solution (w/v) was dissolved in TBST buffer (25mM NaCl, 100mM Tris, 0.2% Tween-20, pH 7.4), PVDF membrane was blocked, primary and secondary antibodies were added for incubation, and then rinsed with TBST buffer, and developed for imaging using SuperECL Plus super luminescent kit.
As shown in FIG. 3, Western Blot results prove that the compound prepared in the above example can induce tumor cell death by inducing tumor cell autophagy, and the ability of promoting tumor autophagy is far better than that of PQ7 in the control group.
In conclusion, the compound in the embodiment of the invention has much better binding capacity to vimentin, autophagy promotion effect on tumor cells and inhibition capacity on tumor cells (including lung cancer cells, liver cancer cells, breast cancer cells, colorectal cancer cells and the like) than PQ7, wherein the chemical structure of the B series compound (embodiments 18-27) is simpler than that of PQ7, and the activity of the B series compound is stronger in all aspects; the C series compounds (examples 5 to 17) have a linear structure similar to that of PQ7, but show stronger binding ability to vimentin than PQ 7.
The embodiments of the present invention have been described in detail with reference to the accompanying drawings, but the present invention is not limited to the above embodiments, and various changes can be made within the knowledge of those skilled in the art without departing from the gist of the present invention. Furthermore, the embodiments of the present invention and the features of the embodiments may be combined with each other without conflict.

Claims (10)

1. A small molecule compound, wherein the structural formula of the small molecule compound is represented by formula (I) or formula (II):
Figure FDA0002919119740000011
wherein, in the formula (I), X comprises carbon, oxygen, nitrogen, sulfur, ester group, carbonyl or amide;
r comprises any open chain compound, carbocycle, heterocycle, halogen, nitryl, cyano-group, amido, hydroxyl or sulfhydryl;
n is any integer of 1-4;
in the formula (II), X comprises carbon, oxygen, nitrogen, sulfur, ester group, carbonyl or amide;
r comprises any open chain compound, carbocycle, heterocycle, halogen, nitryl, cyano-group, amido, hydroxyl or sulfhydryl;
n is any integer of 1-4.
2. The small molecule compound of claim 1, wherein the small molecule compound has a structural formula as shown in formula (II), and the small molecule compound does not comprise:
(1) r is bromine;
(2) n is 2 and R is a structure represented by formula 29;
(3) n is 3 and R is a structure represented by formula 30;
wherein, the structure shown in formula 29 is:
Figure FDA0002919119740000021
the structure shown in formula 30 is:
Figure FDA0002919119740000022
3. the small molecule compound according to claim 1, wherein the small molecule compound comprises a compound having a structure represented by formula 6-28.
4. A composition comprising a small molecule compound according to any one of claims 1 to 3.
5. A method for producing the small molecule compound according to any one of claims 1 to 3, comprising:
demethylating anisoyl in an acidic solution, adding a dibromoalkane chain, adjusting the pH to be alkaline, and adding a cyclic compound or a nitrogen-containing open-chain compound to obtain a micromolecular compound with a structural formula shown in a formula (II);
reacting the micromolecular compound with the structural formula shown as the formula (II) with 1, 2-phenylenediamine under an acidic condition to obtain the micromolecular compound with the structural formula shown as the formula (I);
wherein the cyclic compound comprises an aromatic compound or a heterocyclic compound;
the aromatic compound includes: an aromatic compound containing dimethylamino group, an aromatic compound containing diethylamino group, an aromatic compound containing piperidyl group, an aromatic compound containing piperazinyl group, and benzene;
the heterocyclic compound includes: piperidinyl-containing heterocyclic compounds, piperazinyl-containing heterocyclic compounds, thiophenes, furans, tetrahydropyrrole, and morpholines;
the nitrogen-containing open chain compound includes a dimethylamino open chain compound and a diethylamino open chain compound.
6. The method according to claim 5, wherein the dibromoalkane chain comprises 1, 2-dibromoethane, 1, 3-dibromoethane, and 1, 4-dibromoethane.
7. A pharmaceutical agent comprising the small molecule compound according to any one of claims 1 to 3 or a pharmaceutically acceptable salt thereof.
8. The medicament of claim 7, further comprising a pharmaceutically acceptable excipient.
9. Use of the small molecule compound according to any one of claims 1 to 3 for the preparation of a vimentin detection preparation.
10. The use of a small molecule compound according to any one of claims 1 to 3 for the preparation of an anti-tumor medicament; wherein, the tumor preferably comprises lung cancer, liver cancer, breast cancer and colorectal cancer.
CN202110110479.4A 2021-01-27 2021-01-27 Selective targeting vimentin small molecule compound and preparation method and application thereof Active CN112898232B (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202210536404.7A CN114890965B (en) 2021-01-27 2021-01-27 Small molecular compound of selective targeting vimentin, preparation method and application thereof
CN202110110479.4A CN112898232B (en) 2021-01-27 2021-01-27 Selective targeting vimentin small molecule compound and preparation method and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202110110479.4A CN112898232B (en) 2021-01-27 2021-01-27 Selective targeting vimentin small molecule compound and preparation method and application thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202210536404.7A Division CN114890965B (en) 2021-01-27 2021-01-27 Small molecular compound of selective targeting vimentin, preparation method and application thereof

Publications (2)

Publication Number Publication Date
CN112898232A true CN112898232A (en) 2021-06-04
CN112898232B CN112898232B (en) 2022-08-16

Family

ID=76118827

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202110110479.4A Active CN112898232B (en) 2021-01-27 2021-01-27 Selective targeting vimentin small molecule compound and preparation method and application thereof
CN202210536404.7A Active CN114890965B (en) 2021-01-27 2021-01-27 Small molecular compound of selective targeting vimentin, preparation method and application thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202210536404.7A Active CN114890965B (en) 2021-01-27 2021-01-27 Small molecular compound of selective targeting vimentin, preparation method and application thereof

Country Status (1)

Country Link
CN (2) CN112898232B (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050222155A1 (en) * 2002-04-08 2005-10-06 Bilodeau Mark T Inhibitors of akt activity
KR20120025903A (en) * 2010-09-08 2012-03-16 (주)아모레퍼시픽 A novel quinoxaline compound for ultraviolet absorbers
CN106604939A (en) * 2014-08-25 2017-04-26 日东电工株式会社 Luminescent ethylene-based copolymer, sealing material composition for solar cell, and solar cell module obtained using same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101050213A (en) * 2007-05-14 2007-10-10 中山大学 Fat amido substitutional berberine derviation, preparation method, and application of anticancer drugs
CN108658869A (en) * 2017-03-29 2018-10-16 复旦大学 Compound with anti-tumor activity and preparation method thereof and the purposes in pharmacy
CN107445963B (en) * 2017-06-23 2019-11-05 中山大学 A kind of quinoxaline derivatives and its preparation method and application
KR101871166B1 (en) * 2018-02-27 2018-07-02 (주)오스티오뉴로젠 Novel compound and composition for prevention, improvement or treatment of fibrosis or non-alcoholic steatohepatitis comprising the same
CN111732584B (en) * 2019-03-25 2024-02-27 复旦大学 Diaryl substituted fused heterocycle compound and preparation method and application thereof in pharmacy

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050222155A1 (en) * 2002-04-08 2005-10-06 Bilodeau Mark T Inhibitors of akt activity
KR20120025903A (en) * 2010-09-08 2012-03-16 (주)아모레퍼시픽 A novel quinoxaline compound for ultraviolet absorbers
CN106604939A (en) * 2014-08-25 2017-04-26 日东电工株式会社 Luminescent ethylene-based copolymer, sealing material composition for solar cell, and solar cell module obtained using same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GHAEMY, MOUSA ET AL.: "One-step synthesis of poly(triazole-ether-quinoxaline)s using click reaction: preparation and properties of magnetic nanocomposites with modified Fe3O4 for metal ions removal", 《JOURNAL OF POLYMER RESEARCH》 *

Also Published As

Publication number Publication date
CN112898232B (en) 2022-08-16
CN114890965A (en) 2022-08-12
CN114890965B (en) 2023-09-19

Similar Documents

Publication Publication Date Title
Colina-Vegas et al. Half sandwich Ru (II)-acylthiourea complexes: DNA/HSA-binding, anti-migration and cell death in a human breast tumor cell line
Yang et al. Organotin (IV) complexes derived from Schiff base N’-[(1E)-(2-hydroxy-3-methoxyphenyl) methylidene] pyridine-3-carbohydrazone: Synthesis, in vitro cytotoxicities and DNA/BSA interaction
Jia et al. Synthesis, characterization, and antitumor activity of three ternary dinuclear copper (II) complexes with a reduced Schiff base ligand and diimine coligands in vitro and in vivo
Tan et al. Synthesis, cytotoxic activity, and DNA binding properties of copper (II) complexes with hesperetin, naringenin, and apigenin
CN113603676B (en) Erlotinib-based EGFR protein targeted degradation small molecule compound and preparation method and application thereof
Wang et al. Design, synthesis and biological evaluation of a novel series of glycosylated platinum (iv) complexes as antitumor agents
CN111285851A (en) Compound for targeted degradation of focal adhesion kinase and application thereof in medicine
CN110467633B (en) Main group metal complex and preparation method and application thereof
Van Le et al. Highly cytotoxic gold (i)-phosphane dithiocarbamate complexes trigger an ER stress-dependent immune response in ovarian cancer cells
Rodrigues et al. Synthesis and in vitro efficacy of acid-sensitive poly (ethylene glycol) paclitaxel conjugates
Li et al. Development of a series of flurbiprofen and zaltoprofen platinum (iv) complexes with anti-metastasis competence targeting COX-2, PD-L1 and DNA
CN104119330A (en) Synthesis of berberine derivatives and application of berberine derivatives in preparing anti-tumor drug and anti-tumor drug composition in combination with adriamycin
CN112898232B (en) Selective targeting vimentin small molecule compound and preparation method and application thereof
Anuja et al. Ru (II) arene (N^ N bpy/phen)-based RAPTA complexes for in vitro anti-tumour activity in human glioblastoma cancer cell lines and in vivo toxicity studies in a zebrafish model
CN111440138A (en) Synthesis method of novel urushiol-based hydroxamic acid derivatives having HDAC (Histone deacetylase) inhibition and antitumor activity
CN105418490B (en) Purposes of the mustargen base piperlongumine class compound in medicine
Ke et al. Synthesis and in vitro biological evaluation of novel derivatives of Flexicaulin A condensation with amino acid trifluoroacetate
CN106518933A (en) Ferrocene derivative and preparation method and application thereof
Diehl et al. Synthesis of hydroxyl-functionalized N-heterocyclic carbene gold (i) complexes and peptide conjugates
CN115368306A (en) HDAC (Histone deacetylase) inhibitor containing tetrahydroisoquinoline structure, composition and application thereof
Chen et al. Design, synthesis, and anticancer evaluation of nitrobenzoxadiazole-piperazine hybrids as potent pro-apoptotic agents
CN102391351B (en) Asiatic acid modifier with anti-tumor activity and preparation method of the same
CN109553590B (en) Compound with glutathione mercaptotransferase inhibiting function and preparation method thereof
CN108017608A (en) Flavone derivatives and its preparation method and application
Brustolin et al. Au (III)-Proline derivatives exhibiting selective antiproliferative activity against HepG2/SB3 apoptosis-resistant cancer cells

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant